Investigation of PI3K functional compensation VIA activated tyrosine kinases

buir.advisorÇizmecioğlu, Onur
dc.contributor.authorDemir, Melike
dc.date.accessioned2021-01-08T07:56:25Z
dc.date.available2021-01-08T07:56:25Z
dc.date.copyright2020-12
dc.date.issued2020-12
dc.date.submitted2021-01-06
dc.descriptionCataloged from PDF version of article.en_US
dc.descriptionThesis (M.S.): Bilkent University, Department of Molecular Biology and Genetics, İhsan Doğramacı Bilkent University, 2020.en_US
dc.descriptionIncludes bibliographical references (leaves 52-54).en_US
dc.description.abstractProtein tyrosine kinases and serine-threonine kinases have crucial functions in cell signaling, differentiation, motility, and proliferation. PI3K is the most deregulated pathway in human cancers and an essential regulator of cellular proliferation. PI3K pathway is activated via oncogenic Ras/receptor tyrosine kinases (RTKs), PTEN loss, or activating mutations in PI3Ks. Moreover, PI3K is one of the most promising pathways for targeted therapies. Thus, many serine-threonine or tyrosine kinases contribute to drug resistance elicited by PI3K inhibition. In order to identify an individual tyrosine kinase that contributes to PI3K functional compensation, the activated tyrosine kinase library was screened and found out that ZAP70 can compensate growth upon PI3K abrogation. This study suggests a mechanism of activated ZAP70 mediated partial resistance in MEFs lines. Moreover, we demonstrated the role of activated tyrosine kinase, ZAP70, in cancer cells as a tumorinitiating factor. Activated ZAP70 is able to enhance the growth ability of untransformed cells. Also in these cells, activated ZAP70 can develop partial resistance to PI3K inhibition. This resistance occurs via activated downstream targets of tyrosine kinase signaling such as STAT3/MAPK axis. Furthermore, we showed that activated ZAP70 has a high transformation capability associated with the formation of malignant phenotype in untransformed cells. Overall, ZAP70 may be a potent driver of proliferation and transformation in untransformed cells as well as in cancer cells.en_US
dc.description.provenanceSubmitted by Betül Özen (ozen@bilkent.edu.tr) on 2021-01-08T07:56:25Z No. of bitstreams: 1 Melike_Demir_Tez.pdf: 3540561 bytes, checksum: d1aac1057ad272664dc7230022c17e69 (MD5)en
dc.description.provenanceMade available in DSpace on 2021-01-08T07:56:25Z (GMT). No. of bitstreams: 1 Melike_Demir_Tez.pdf: 3540561 bytes, checksum: d1aac1057ad272664dc7230022c17e69 (MD5) Previous issue date: 2021-01en
dc.description.statementofresponsibilityby Melike Demiren_US
dc.embargo.release2021-07-07
dc.format.extentvi, 54 leaves : illustrations, color charts ; 30 cm.en_US
dc.identifier.itemidB154070
dc.identifier.urihttp://hdl.handle.net/11693/54871
dc.language.isoEnglishen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectPI3Ken_US
dc.subjectTyrosine kinasesen_US
dc.subjectDrug resistanceen_US
dc.subjectCell signalingen_US
dc.titleInvestigation of PI3K functional compensation VIA activated tyrosine kinasesen_US
dc.title.alternativeAktive edilmiş tirozin kinaz aracılı PI3K fonksiyonel kompensasyonunun araştırılmasıen_US
dc.typeThesisen_US
thesis.degree.disciplineMolecular Biology and Genetics
thesis.degree.grantorBilkent University
thesis.degree.levelMaster's
thesis.degree.nameMS (Master of Science)

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Melike_Demir_Tez.pdf
Size:
3.38 MB
Format:
Adobe Portable Document Format
Description:
Full printable version

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: